Whitehawk Therapeutics Inc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $194.4M
- Price
- $3.41
- % Change (Daily % change from the live per-ticker quote feed.)
- -5.54%
- Volume
- 435.7K
About
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Quick stats
Shares outstanding57.0M
Computed float18.0M
Float / shares31.5%
Cash runway (months)28.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001422142
Websitehttps://ir.whitehawktx.com
AI Summary
AI-generated1/21
minorbullishclinical trial
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
Whitehawk Therapeutics presented two real-world analyses at IGCS 2026 supporting MUC16 as a durable ADC target in ovarian cancer.
MUC16 expression remained high and stable after standard-of-care therapies and showed less treatment-associated variation than competing ADC targets FRα, TROP2 and NaPi2b; high MUC16 expression was also prognostic of poor real-world overall survival in HGSOC, the subtype accounting for roughly 70% of ovarian cancer cases.
The findings reinforce the scientific rationale for HWK-016, Whitehawk's MUC16-directed ADC in an ongoing Phase 1 trial (NCT07470853), and stem from a previously announced collaboration with Tempus AI.
Red flags
- Real-world biomarker data, not clinical efficacy data from HWK-016's own Phase 1 trial